A Phase 2 interventional study of Sarilumab and Placebo in Rheumatoid Arthritis, sponsored by Sanofi. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 4 that started in 2010, is the only one in phase 2, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 33rd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2010, is one of 7 in phase 2, and was the 11th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
The duration of the study period for each participant was approximately 22 weeks; including up to 4 weeks screening period, 12-week double-blind treatment period and 6-week safety follow-up period.
Participants who completed the 12-week treatment period were offered enrollment in a separate long-term extension study (LTS11210/NCT01146652).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active disease defined as:
Participant considered as Primary TNF-α blocker nonresponder. i.e.:
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
Drug: Placebo · Drug: methotrexate (MTX) · Drug: Folic/folinic acid
Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
Drug: Placebo · Drug: Golimumab · Drug: methotrexate (MTX) · Drug: Folic/folinic acid
Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
Drug: Sarilumab · Drug: Placebo · Drug: methotrexate (MTX) · Drug: Folic/folinic acid
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: SAR153191, REGN88
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Simponi®
Pharmaceutical form: tablet or solution for injection Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Drug page: Leucovorin
Pharmaceutical form: tablet Route of administration: oral Folic/folinic acid continued according to local standard.
Percentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12
Time frame: Week 12
Percentage of Participants Who Achieved at Least 50% Improvement in American College of Rheumatology (ACR50) Core Set Disease Activity Index at Week 12
Time frame: Week 12
Percentage of Participants Who Achieved at Least 70% Improvement in American College of Rheumatology Core (ACR70) Set Disease Activity Index at Week 12
Time frame: Week 12
Disease Activity Score for 28 Joints (DAS28) at Week 12
Time frame: Week 12
European League Against Rheumatism (EULAR) Response at Week 12
Time frame: Week 12
Percentage of Participants Achieving DAS28 Remission Score < 2.6 at Week 12
Time frame: Week 12
Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab
Time frame: Week 12
The study was conducted at 10 centers in United States and Europe. A total of 41 participants were screened between 15 November 2010 and 18 May 2011 of whom 16 participants were randomized and 25 were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Placebo | Golimumab 50 mg | Sarilumab 150 mg |
|---|---|---|---|
| Started | 4 | 5 | 7 |
| Completed | 3 | 4 | 6 |
| Not completed | 1 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| ng/mL | Sarilumab 150 mg qw |
|---|---|
| Bound Concentration | 4271.43 ± 1328.86 |
| Functional Concentration | 42391.43 ± 26168.68 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (week 18) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/4 (0%) | 3/4 (75%) |
| Golimumab 50 mg | — | 0/5 (0%) | 1/5 (20%) |
| Sarilumab 150 mg | — | 0/7 (0%) | 3/7 (42.9%) |
| Event | Placebo | Golimumab 50 mg | Sarilumab 150 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/4 | 0/5 | 0/7 |
| SinusitisInfections and infestations | 1/4 | 0/5 | 0/7 |
| Urinary tract infectionInfections and infestations | 1/4 | 0/5 | 0/7 |
| UrticariaSkin and subcutaneous tissue disorders | 1/4 | 0/5 | 0/7 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/4 | 0/5 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 1/5 | 0/7 |
| VomitingGastrointestinal disorders | 0/4 | 1/5 | 0/7 |
| DermatitisSkin and subcutaneous tissue disorders | 0/4 | 1/5 | 0/7 |
| InfluenzaInfections and infestations | 0/4 | 0/5 | 1/7 |
| HypertensionVascular disorders | 0/4 | 0/5 | 1/7 |
| Age, Continuous(years) | Placebo | Golimumab 50 mg | Sarilumab 150 mg | Total |
|---|---|---|---|---|
| Mean | 45.3 ± 17.9 | 62.6 ± 7.6 | 54.0 ± 11.1 | 54.5 ± 13.2 |
| Sex: Female, Male(Participants) | Placebo | Golimumab 50 mg | Sarilumab 150 mg | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 7 | 14 |
| Male | 0 | 2 | 0 | 2 |
The record gives a start of Nov 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2017, 6 years after primary completion. A results delay was requested in Oct 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab